Anti-Claudin-18 isoform2 (CLDN18.2)-Anti-CD3 IgG format bispecific antibody is a purified recombinant human bispecific antibody with T cell Engager. This bispecific antibody has been tested for specific activity in the functional reporter assay using NFAT-luc reporter Jurkat cell line (BPS Bioscience #60621) in the presence of CLDN18.2-CHO cells (BPS Bioscience #78533-H) that overexpress CLDN18.2.
assay conditions: Experimental design and assay protocol for measuring anti-CLDN18.2-anti-CD3 functional activity using NFAT-luc reporter Jurkat cell line:Jurkat effector cells with endogenous TCR/CD3 and transfected reporter NFAT-luc (BPS Bioscience #60621) are incubated with increasing concentrations of anti-CLDN18.2 x anti-CD3 bispecific antibody in the presence of CLDN18.2-CHO cells (BPS Bioscience #78533-H) or CHO cells (ATCC #CCL61).1. Seed CHO and CLDN18.2-CHO cells at 30,000 cells/well and allow a few hours for the cells to attach in a 96-well clear bottom white plate.2. Seed Jurkat cells at 30,000 cells/well.3. Add the bispecific antibody at a recommended dilution range of 100 fM-100 nM. The bispecific antibody simultaneously binds to TCR/CD3 on the NFAT-luc Jurkat reporter cells and tumor antigen CLDN18.2 on CLDN18.2-CHO cells.4. After 16 hours the luciferase activity is measured using ONE-Step Luciferase Assay (BPS Bioscience #60690) per recommended protocol. The bispecific antibody interaction stimulates NFAT-luciferase activity.
Formulation
8 mM phosphate, pH 7.4, 110 mM NaCl, 2.2 mM KCl, and 20% glycerol
Host
Heavy chain (HC) and Light chain (LC) co-expressed in HEK293